Brazil approves emergency use of Chinese Sinovac, AstraZeneca COVID-19 vaccines


SAO PAULO, Jan. 17 (Xinhua) -- Brazil's Health Regulatory Agency (Anvisa) unanimously approved on Sunday the emergency use of the CoronaVac vaccine, from the Chinese laboratory Sinovac, as well as the AstraZeneca-University of Oxford vaccine against COVID-19.

The decision will allow the Brazilian government to start its vaccination plan against COVID-19 with 6 million doses of the CoronaVac vaccine, developed by Sinovac in conjunction with the Butantan Institute of Sao Paulo.

"The moment is for awareness, unity, and work. There is only one enemy. Our chance, our best chance in this war is, necessarily, for a change in social behavior, without which, even with vaccines, victory will not be achieved," said the director-president of Anvisa, Antonio Barra Torres.

Torres led the Anvisa leadership meeting, broadcast live on television, which gave the decision after analyzing the emergency registration requests for the two coronavirus vaccines.

Brazil is second in the world in the number of deaths from COVID-19, with 209,296 deaths as of Saturday, and third in the world in the number of cases, with more than 8.4 million infections reported.

The governor of Sao Paulo, Joao Doria, wrote on Twitter, "Brazil is in a hurry to save lives."

Doria followed the Anvisa vote at the Hospital de Clinicas, the largest public medical center in Latin America, according to his press office.

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 18
Cxense type: free
User access status: 3
   

Did you find this article insightful?

Yes
No

100% readers found this article insightful

Next In World

Saudi-led coalition destroys five Houthi drones - Saudi TV
This US startup is building tiny injectable robots to attack tumours
South Korea, U.S. scale back military drill over coronavirus
Biden marks Selma anniversary with order to expand voting access
Manhattan’s real estate agents take up TikTok to find renters
New Zealand's Auckland emerges from lockdown, Australia starts AstraZeneca vaccinations
A crisis with a woman’s face
Why it's so hard for survivors to come forward
Boy killed in Senegal protests as opposition steps up pressure
U.S. scientists doubtful of one-shot regimen for Pfizer, Moderna COVID vaccines - WSJ

Stories You'll Enjoy


Vouchers